Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus erlotinib as salvage treatment in EGFR-overexpressed metastatic colorectal cancer
KCT0003757Phase 2Active, not recruiting
- Sponsor
- HK inno.N Corporation
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, erlotinib in metastatic colon cancer (mCRC), Nonhematologic neoplasms, sponsored by HK inno.N Corporation. Started May 2017; status: active, not recruiting.
02
Drugs
pemetrexederlotinib
03
Conditions
metastatic colon cancer (mCRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0003757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003757.